SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1588949
Prognostic value of pretreatment systemic immune-inflammation index in esophageal squamous cell carcinoma: A meta-analysis
Provisionally accepted
- Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
In recent years, the Systemic Immunoinflammatory Index (SII), a novel metric that shows great potential for tumor assessment and therapeutic strategy development, has growing evidence supporting its prognostic relevance across multiple cancer types. Although some studies have linked SII to the prognosis of esophageal squamous cell carcinoma (ESCC), the results are still controversial. To this end, we carried out a meta-analysis to explore the value of SII in the prognosis of ESCC patients.The literature was systematically searched in Web of Science, Embase and PubMed databases, covering available records from database creation to September 2024. Pre-treatment SII was extracted from published studies, and the prognostic value of pre-treatment SII was assessed by calculating the odds ratio (OR), hazard ratio (HR), and the corresponding 95% confidence intervals (CI), which were combined in meta-analyses. The primary outcome metrics include overall survival (OS), disease-free survival (DFS)/progression-free survival (PFS).Results: Our meta-analysis incorporated six qualified studies comprising a total cohort of 2712 patients. Pooled data observed that patients with increased SII values displayed values exhibited poorer overall survival (OS) (HR=1.80, 95% CI=1.38-2.36, p<0.0001) and shorter disease-free survival (DFS)/progression-free survival (PFS) (HR=1.94, 95% CI=1.60-2.35, p<0.00001).Additionally, a high SII was strongly correlated with the end TNM stage (III-IV vs. I-II; OR=1.
Keywords: Esophageal squamous cell carcinoma (ESCC), Systemic immune-inflammation index (SII), prognosis, biomarkers, Meta-analysis
Received: 06 Mar 2025; Accepted: 14 May 2025.
Copyright: © 2025 He, Chen, He, Zhang, Zhao, Sun, Li and Lai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Zhichao Lai, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.